美国脆弱拟杆菌群的药敏性：按分离部位分析
Susceptibility of the Bacteroides fragilis group in the United States: analysis by site of isolation.
作者信息
Cuchural G J, Tally F P, Jacobus N V, Aldridge K, Cleary T, Finegold S M, Hill G, Iannini P, O'Keefe J P, Pierson C
机构信息
Department of Medicine, Tufts-New England Medical Center Hospitals, Boston, Massachusetts 02111.
出版信息
Antimicrob Agents Chemother. 1988 May;32(5):717-22. doi: 10.1128/AAC.32.5.717.
Abstract
An ongoing survey of the susceptibility of the Bacteroides fragilis group of bacteria was continued at New England Medical Center in 1984 and 1985. A total of 1,229 strains were obtained from eight centers in the United States. These results were compared with those for 1,847 isolates tested in 1981 through 1983. The most active beta-lactam drugs were imipenem and ticarcillin-clavulanic acid (Timentin), which had a less than 1% resistance rate. No metronidazole- or chloramphenicol-resistant isolates were found during the 5 years of the study. Isolates obtained from blood, perinatal, and bone sites of infection were more resistant to a variety of antimicrobial agents. Susceptibility patterns of the members of the B. fragilis group varied at the eight hospitals and among species. These data indicate the need for determining the susceptibility patterns for the B. fragilis group of organisms at each hospital.
摘要
1984年和1985年，新英格兰医学中心继续对脆弱拟杆菌菌群的药敏情况进行一项持续调查。共从美国八个中心获取了1229株菌株。这些结果与1981年至1983年检测的1847株分离株的结果进行了比较。活性最强的β-内酰胺类药物是亚胺培南和替卡西林-克拉维酸（特美汀），耐药率低于1%。在该研究的5年期间未发现耐甲硝唑或耐氯霉素的分离株。从血液、围产期和骨感染部位获得的分离株对多种抗菌药物更具耐药性。脆弱拟杆菌菌群各成员的药敏模式在八家医院以及不同菌种之间存在差异。这些数据表明有必要在每家医院确定脆弱拟杆菌菌群生物体的药敏模式。
相似文献
1
Susceptibility of the Bacteroides fragilis group in the United States: analysis by site of isolation.美国脆弱拟杆菌群的药敏性：按分离部位分析
Antimicrob Agents Chemother. 1988 May;32(5):717-22. doi: 10.1128/AAC.32.5.717.
2
Antimicrobial susceptibilities of 1,292 isolates of the Bacteroides fragilis group in the United States: comparison of 1981 with 1982.美国1292株脆弱拟杆菌属细菌的药敏情况：1981年与1982年的比较
Antimicrob Agents Chemother. 1984 Aug;26(2):145-8. doi: 10.1128/AAC.26.2.145.
3
Nationwide study of the susceptibility of the Bacteroides fragilis group in the United States.美国全国范围内脆弱拟杆菌群药敏性研究。
Antimicrob Agents Chemother. 1985 Nov;28(5):675-7. doi: 10.1128/AAC.28.5.675.
4
Antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1989.1989年美国脆弱拟杆菌群的抗菌药敏模式
Clin Ther. 1992 Jan-Feb;14(1):122-36.
5
Changes in the susceptibility of Bacteroides fragilis group organisms to various antimicrobial agents 1979-1989.1979 - 1989年间脆弱拟杆菌属菌群对各种抗菌药物敏感性的变化
Eur J Clin Microbiol Infect Dis. 1992 Apr;11(4):352-6. doi: 10.1007/BF01962077.
6
Newer beta-lactam agents and the Bacteroides fragilis group.新型β-内酰胺类药物与脆弱拟杆菌群
Pharmacotherapy. 1991;11(2 ( Pt 2)):51S-55S.
7
The antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1987.1987年美国脆弱拟杆菌群的抗菌药敏模式。
J Antimicrob Chemother. 1990 Jun;25(6):1011-9. doi: 10.1093/jac/25.6.1011.
8
Beta-lactamase production, beta-lactam sensitivity and resistance to synergy with clavulanate of 737 Bacteroides fragilis group organisms from thirty-three US centres.来自美国33个中心的737株脆弱拟杆菌属微生物的β-内酰胺酶产生情况、β-内酰胺敏感性以及与克拉维酸协同作用的耐药性
J Antimicrob Chemother. 1990 Sep;26(3):361-70. doi: 10.1093/jac/26.3.361.
9
Susceptibility of 114 isolates of the Bacteroides fragilis group to imipenem and eight other antimicrobial agents.114株脆弱拟杆菌属菌株对亚胺培南及其他8种抗菌药物的敏感性
Pathology. 1988 Jul;20(3):260-3. doi: 10.3109/00313028809059504.
10
Comparative activities of newer beta-lactam agents against members of the Bacteroides fragilis group.新型β-内酰胺类药物对脆弱拟杆菌群成员的比较活性
Antimicrob Agents Chemother. 1990 Mar;34(3):479-80. doi: 10.1128/AAC.34.3.479.
引用本文的文献
1
Trends in the susceptibility of commonly encountered clinically significant anaerobes and susceptibilities of blood isolates of anaerobes to 16 antimicrobial agents, including fidaxomicin and rifaximin, 2008-2012, northern Taiwan.2008 - 2012年台湾北部常见临床重要厌氧菌的药敏趋势以及厌氧菌血液分离株对包括非达霉素和利福昔明在内的16种抗菌药物的药敏情况
Eur J Clin Microbiol Infect Dis. 2014 Nov;33(11):2041-52. doi: 10.1007/s10096-014-2175-y. Epub 2014 Jun 15.
2
Prevalence of antimicrobial resistance among clinical isolates of Bacteroides fragilis group in Canada in 2010-2011: CANWARD surveillance study.2010-2011 年加拿大脆弱拟杆菌群临床分离株的抗菌药物耐药性流行情况：CANWARD 监测研究。
Antimicrob Agents Chemother. 2012 Mar;56(3):1247-52. doi: 10.1128/AAC.05823-11. Epub 2011 Dec 27.
3
Bacteremia due to Bacteroides fragilis group: distribution of species, beta-lactamase production, and antimicrobial susceptibility patterns.脆弱拟杆菌群所致菌血症：菌种分布、β-内酰胺酶产生情况及抗菌药物敏感性模式
Antimicrob Agents Chemother. 2003 Jan;47(1):148-53. doi: 10.1128/AAC.47.1.148-153.2003.
4
In vitro susceptibilities of the Bacteroides fragilis group species: change in isolation rates significantly affects overall susceptibility data.脆弱拟杆菌群菌种的体外药敏：分离率的变化显著影响总体药敏数据。
J Clin Microbiol. 2002 Nov;40(11):4349-52. doi: 10.1128/JCM.40.11.4349-4352.2002.
5
Distribution of the cfiA gene among Bacteroides fragilis strains in Japan and relatedness of cfiA to imipenem resistance.日本脆弱拟杆菌菌株中cfiA基因的分布及cfiA与亚胺培南耐药性的相关性
Antimicrob Agents Chemother. 1999 Nov;43(11):2808-10. doi: 10.1128/AAC.43.11.2808.
6
Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996.1995年至1996年脆弱拟杆菌群体外药敏的多中心研究，以及1990年至1996年耐药趋势比较
Antimicrob Agents Chemother. 1999 Oct;43(10):2417-22. doi: 10.1128/AAC.43.10.2417.
7
beta-Lactamases in laboratory and clinical resistance.实验室及临床耐药中的β-内酰胺酶
Clin Microbiol Rev. 1995 Oct;8(4):557-84. doi: 10.1128/CMR.8.4.557.
8
In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis.硝基咪唑类化合物CGI 17341对结核分枝杆菌的体外和体内活性
Antimicrob Agents Chemother. 1993 Feb;37(2):183-6. doi: 10.1128/AAC.37.2.183.
9
Rationale for selective use of anaerobic blood cultures.选择性使用厌氧血培养的基本原理。
J Clin Microbiol. 1993 Aug;31(8):2110-3. doi: 10.1128/jcm.31.8.2110-2113.1993.
10
Cloning and characterization of the endogenous cephalosporinase gene, cepA, from Bacteroides fragilis reveals a new subgroup of Ambler class A beta-lactamases.来自脆弱拟杆菌的内源性头孢菌素酶基因cepA的克隆与特性分析揭示了安布勒A类β-内酰胺酶的一个新亚组。
Antimicrob Agents Chemother. 1993 Nov;37(11):2391-400. doi: 10.1128/AAC.37.11.2391.
本文引用的文献
1
Antibacterial activity of new beta-lactam antibiotics on cefoxitin-resistant strains of Bacteroides fragilis.
J Antimicrob Chemother. 1980 Mar;6(2):207-16. doi: 10.1093/jac/6.2.207.
2
Susceptibility of the Bacteroides fragilis group in the United States in 1981.1981年美国脆弱拟杆菌群的药敏情况。
Antimicrob Agents Chemother. 1983 Apr;23(4):536-40. doi: 10.1128/AAC.23.4.536.
3
Improved localization and survival in patients with intraabdominal abscesses.腹腔内脓肿患者定位及生存率的改善
Am J Surg. 1983 Jan;145(1):136-42. doi: 10.1016/0002-9610(83)90180-0.
4
Cefoxitin inactivation by Bacteroides fragilis.脆弱拟杆菌对头孢西丁的灭活作用。
Antimicrob Agents Chemother. 1983 Dec;24(6):936-40. doi: 10.1128/AAC.24.6.936.
5
Antimicrobial susceptibilities of 1,292 isolates of the Bacteroides fragilis group in the United States: comparison of 1981 with 1982.美国1292株脆弱拟杆菌属细菌的药敏情况：1981年与1982年的比较
Antimicrob Agents Chemother. 1984 Aug;26(2):145-8. doi: 10.1128/AAC.26.2.145.
6
Mechanisms of resistance and resistance transfer in anaerobic bacteria: factors influencing antimicrobial therapy.厌氧菌的耐药机制及耐药性转移：影响抗菌治疗的因素
Rev Infect Dis. 1984 Mar-Apr;6 Suppl 1:S260-9. doi: 10.1093/clinids/6.supplement_1.s260.
7
Anaerobic infections. 1.厌氧感染。1.
N Engl J Med. 1974 May 23;290(21):1177-84. doi: 10.1056/NEJM197405232902106.
8
Nationwide study of the susceptibility of the Bacteroides fragilis group in the United States.美国全国范围内脆弱拟杆菌群药敏性研究。
Antimicrob Agents Chemother. 1985 Nov;28(5):675-7. doi: 10.1128/AAC.28.5.675.
9
Randomized, prospective, and double-blind trial of new beta-lactams in the treatment of appendicitis.新型β-内酰胺类药物治疗阑尾炎的随机、前瞻性、双盲试验
Antimicrob Agents Chemother. 1985 Nov;28(5):639-42. doi: 10.1128/AAC.28.5.639.
10
Susceptibility of anaerobes to cefoxitin and other cephalosporins.厌氧菌对头孢西丁及其他头孢菌素的敏感性。
Antimicrob Agents Chemother. 1975 Feb;7(2):128-32. doi: 10.1128/AAC.7.2.128.
Zotero 插件